Recently Approved

December 2007
Pharmaceutical Representative;Dec2007, Vol. 37 Issue 12, p16
The article presents information about the latest approved drugs in the U.S. The Food and Drug Administration (FDA) has cleared Ortho-McNeil Inc.'s Doribax for the treatment of complicated intra-abdominal infections and urinary tract infections. GlaxoSmithKline's new oral capsule formulation Hycamtin has been approved for the treatment of relapsed small cell lung cancer patients. The FDA has granted Merck & Co. Inc.'s Isentress tablets for use in treating HIV-1 infection.


Related Articles

  • Product Preview.  // Urology Times;4/1/2005, Vol. 33 Issue 4, p39 

    The article presents news regarding drug development for prostate cancer. It reports that the Food and Drug Administration (FDA) of the United States has agreed to file the new drug application for atrasentan by Abbott, an oral agent for the treatment of metastatic hormone-refractory prostate...

  • Topamax approved as stand-alone therapy.  // Drug Topics;7/11/2005, Vol. 149 Issue 13, p6 

    Reports that the U.S. Food and Drug Administration has approved the use of Ortho-McNeil Pharmaceutical Inc.'s anti-epilepsy drug, Topamax (topiramate) Tablets and Sprinkle Capsules, as initial monotherapy in patients with partial-onset or primary generalized tonic-clonic seizures.

  • Topiramate labeling warns of acidosis risk.  // Drug Topics;1/12/2004, Vol. 148 Issue 1, p9 

    Reports that Ortho-McNeil and the U.S. Food and Drug Administration (FDA) have modified the "warnings" and "precautions" sections of the labeling for topiramate (Topomax). Goal to inform healthcare professionals that the drug causes hyperchloremic, non-anion gap acidosis.

  • A new wrinkle.  // Business News New Jersey;1/10/96, Vol. 9 Issue 1, p3 

    Reports that Johnson & Johnson subsidiary Ortho has a drug called Renova which was approved by the Food & Drug Administration (FDA) to reduce facial wrinkles. Information on Johnson & Johnson guilty plead in 1994; Destroyed evidence of investigation by FDA on previous formula.

  • Reactions, misuse with pain medication.  // FDA Consumer;Jul/Aug96, Vol. 30 Issue 6, p4 

    Reports on the Food and Drug Administration's (FDA) efforts to work with Ultram manufacturer Ortho McNeil to develop new labeling that discourages doctors from prescribing the pain reliever to patients with a history of opioid addiction or dependence. FDA's receipt of reports of drug abuse,...

  • Birth control pill can treat acne.  // Dermatology Times;Feb97, Vol. 18 Issue 2, p4 

    Reports that the birth control pill manufactured by Ortho Pharmaceuticals and sold under the name Ortho Tri-Cyclen has been granted approval by the Food & Drug Administration (FDA) as treatment for acne.

  • Ortho given nod by FDA to sell antiaging cream.  // WWD: Women's Wear Daily;1/3/1996, Vol. 171 Issue 2, p11 

    Reports on the US Food and Drug Administration's approval for Ortho Pharmaceutical Corp.'s Renova antiaging cream. Use of alpha hydroxy products.

  • New Warning on Birth Control Patch.  // FDA Consumer;Jan/Feb2006, Vol. 40 Issue 1, p4 

    The article reports that the U.S. Food and Drug Administration approved the updated warning label for the Ortho Eva contraceptive patch manufactured by Ortho-McNeil Pharmaceutical Inc. as of January 2006. It describes how the patch works and states the new warning label for the patch. It reveals...

  • Regranex now available in prescription strength. Shaw, Kendall // Discount Store News;5/25/98, Vol. 37 Issue 10, pCP22 

    Reports on the US Food & Drug Administration's approval of the Regranex drug indicated for diabetic neuropathic foot ulcers and developed by Ortho-McNeil Pharmaceutical Corp.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics